BIOCHEMICAL ACTIONS OF L-DEPRENYL (SELEGILINE)

被引:21
作者
LANGE, KW [1 ]
RIEDERER, P [1 ]
YOUDIM, MBH [1 ]
机构
[1] TECHNION ISRAEL INST TECHNOL, FAC MED, DEPT PHARMACOL, HAIFA, ISRAEL
关键词
D O I
10.1038/clpt.1994.203
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
l-Deprenyl is a selective, irreversible monoamine oxidase (MAO) type B inhibitor. Dopamine is a relatively good MAO-B substrate in the human brain. Because Parkinson's disease is characterized by a decrease in dopaminergic neurotransmission in the basal ganglia, the selective inhibition of MAO-B should lead to diminished metabolism of dopamine in the nigostriatal system and a significant increase in the concentration of the neurotransmitter. MAO-B inhibition explains the clinical efficacy of l-deprenyl in the treatment of Parkinson's disease and the prevention of the conversion of protoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which is oxidized by MAO-B and can cause a parkinsonian syndrome, to their active neurotoxin. In addition, l-deprenyl appears to exhibit other biochemical actions that are independent of its MAO-B activity. These actions may be the basis of the neuroprotective effects of l-deprenyl and may include the inhibition of oxidative stress, an indirect influence on the polyamine binding site of the N-methyl-d-aspartate receptor and the stimulation of neurotrophic factors.
引用
收藏
页码:734 / 741
页数:8
相关论文
共 89 条
[1]   CDNA CLONING OF HUMAN-LIVER MONOAMINE OXIDASE-A AND OXIDASE-B - MOLECULAR-BASIS OF DIFFERENCES IN ENZYMATIC-PROPERTIES [J].
BACH, AWJ ;
LAN, NC ;
JOHNSON, DL ;
ABELL, CW ;
BEMBENEK, ME ;
KWAN, SW ;
SEEBURG, PH ;
SHIH, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4934-4938
[2]  
BALLARD PA, 1985, NEUROLOGY, V35, P969
[3]   THE IRON CHELATOR DESFERRIOXAMINE (DESFERAL) RETARDS 6-HYDROXYDOPAMINE-INDUCED DEGENERATION OF NIGROSTRIATAL DOPAMINE NEURONS [J].
BENSHACHAR, D ;
ESHEL, G ;
FINBERG, JPM ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 56 (04) :1441-1444
[4]   INCREASED LIFE EXPECTANCY RESULTING FROM ADDITION OF L-DEPRENYL TO MADOPAR TREATMENT IN PARKINSONS-DISEASE - A LONGTERM STUDY [J].
BIRKMAYER, W ;
KNOLL, J ;
RIEDERER, P ;
YOUDIM, MBH ;
HARS, V ;
MARTON, J .
JOURNAL OF NEURAL TRANSMISSION, 1985, 64 (02) :113-127
[5]   POTENTIATION OF ANTI AKINETIC EFFECT AFTER L-DOPA TREATMENT BY AN INHIBITOR OF MAO-B, DEPRENIL [J].
BIRKMAYER, W ;
RIEDERER, P ;
YOUDIM, MBH ;
LINAUER, W .
JOURNAL OF NEURAL TRANSMISSION, 1975, 36 (3-4) :303-326
[6]  
Birkmayer W, 1983, Mod Probl Pharmacopsychiatry, V19, P170
[7]  
BIRKMAYER W, 1977, LANCET, V1, P439
[8]   HYPERTENSIVE INTERACTIONS BETWEEN MONOAMINE OXIDASE INHIBITORS AND FOODSTUFFS [J].
BLACKWELL, B ;
MARLEY, E ;
PRICE, J ;
TAYLOR, D .
BRITISH JOURNAL OF PSYCHIATRY, 1967, 113 (497) :349-+
[9]   THE CLINICAL SYNDROME OF STRIATAL DOPAMINE DEFICIENCY - PARKINSONISM INDUCED BY 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) [J].
BURNS, RS ;
LEWITT, PA ;
EBERT, MH ;
PAKKENBERG, H ;
KOPIN, IJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (22) :1418-1421
[10]  
CARILLO MC, 1991, LIFE SCI, V48, P517